A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis
Market
0.0%
Details
- Resolved Date
- 2/27/25
- Study Completion
- 3/1/26
- Company
- Beijing InnoCare Pharma Tech Co., Ltd.
- Ticker
- 09969.HK
- Type
- Trial Status
- Unknown
- Trial Size
- 160
- Volume
- $0
- NCT
- NCT04711148
- Drug Description
- This is a randomized, double-Blind, placebo-controlled Phase 2 Study of Orelabrutinib in Patients with Relapsing-Remitting Multiple Sclerosis.
Resolution Evidence
- Outcome
- YES
- Status
- Resolved
- Settlement Date
- 4/1/26 UTC
- Executive Summary
Public sources clearly frame NCT04711148 as positive. A trial-specific report says the Phase 2 study was highly effective, with statistically significant primary-endpoint lesion reductions, and InnoCare later described the Phase II MS results as highly effective and used 80 mg QD to support Phase III selection.
Sources
Web Searchneurologylive.com2/27/25
BTK Inhibitor Orelabrutinib Shows Promising Efficacy in Phase 2 Study of Relapsing-Remitting Multiple Sclerosis
Trial-specific report on NCT04711148: orelabrutinib was described as highly effective; all active arms had statistically significant reductions in the primary endpoint at week 12, with 80 mg QD most effective.
View source
Sponsorbusinesswire.com3/27/25
InnoCare Releases 2024 Results and Business Highlights
Sponsor-linked summary says the Phase II MS results showed orelabrutinib was highly effective in RRMS, and 80 mg once daily had the best efficacy/safety profile and was selected for Phase III studies.
View source
Activity Feed
No activity entries match the current filters for this market.
Model Positions
